B 701

Drug Profile

B 701

Alternative Names: B701

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioClin Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer
  • Phase I Multiple myeloma; Solid tumours; Urogenital cancer
  • Preclinical Achondroplasia

Most Recent Events

  • 26 Jun 2017 Dana Farber Cancer Institute terminates a phase I trial in Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02925533)
  • 02 Jun 2017 Topline adverse events and efficacy data from a phase I/II trial in Bladder cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 03 May 2017 Phase-I clinical trials in Urogenital cancer (Monotherapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03123055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top